CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

by | Jun 6, 2025 | Clinical Trials | 0 comments

​ Conditions: CD7+ Lymphoma; CD7+ Acute Leukemia

Interventions: Biological: CD7 CART

Sponsors: Qi deng; Hebei Taihe Chunyu Biotechnology Co., Ltd

Not yet recruiting Conditions: CD7+ Lymphoma; CD7+ Acute Leukemia
Interventions: Biological: CD7 CART
Sponsors: Qi deng; Hebei Taihe Chunyu Biotechnology Co., Ltd
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *